Currently, recombinant porcine FVIII (rpFVIII) has a purity greater than 99%, which significantly reduces the risk of adverse events, such as thrombocytopenia and hypersensitivity reactions, commonly associated with purified porcine FVIII concentrate. The gene discussed is F8; the disease is Thrombocytopenia.